secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0000950170-25-012846
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology initiates combo trial PYX-201 + Keytruda and monotherapy expansion in HNSCC
--------------------------------------------------------------------------------

- Phase 1/2 combo trial PYX-201-102 with Keytruda (pembrolizumab) in multiple solid tumors including R/M HNSCC, HR+/HER2- BC, TNBC; first dosing on track for Q1 2025.
- Part 2 monotherapy expansion cohorts of Phase 1 PYX-201-101 began enrolling for 2L/3L R/M HNSCC patients who received prior platinum and PD-1 or EGFR and PD-1 inhibitors.
- PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin (EDB+FN) in tumor extracellular matrix, designed to induce immunogenic cell death.
- Combo trial is part of a Clinical Trial Collaboration Agreement with Merck (MRK).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025012846/0000950170-25-012846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025012846/pyxs-20250204.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-012846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer